Inactivated vaccine protects against severe outcome among adults aged over 60 years during SARS-CoV-2 Omicron variant predominance: evidence from a single-center cohort
SUN Feng1, ZHANG Yilin1, LI Yang1, ZHANG Haocheng1, LIU Qihui1, AI Jingwen1, WANG Sen1, CUI Shuzheng2, SHI Liubin2, XUE Yu2, LONG Feng2, MA Ke2, QIN Lunxiu2, ZHANG Jiming1, ZHANG Wenhong1
1. Department of Infectious Diseases, National Clinical Research Center for Aging and Medicine, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai 201907, China; 2. Huashan Hospital, Baoshan Campus, Fudan University, Shanghai 201907, China
Abstract：The purpose of the current study is to investigate the association between vaccination status and clinical outcomes in the elderly during the Omicron wave. A total of 1 029 patients aged 60 years or older were hospitalized in Huashan Hospital of Fudan University, Baoshan Campus from March 20 to May 6, 2022 (643 cases unvaccinated, 386 cases vaccinated). Demographic characteristics, clinical symptoms, laboratory findings, and clinical outcomes were compared, and multivariate regression was applied to determine association between vaccination status and clinical outcomes. Results indicated a significant difference in age, BMI, comorbidity (diabetes, cardiovascular disease, chronic kidney disease), number of comorbidities, and laboratory findings (lymphocyte counts, C-reactive protein, D-dimer, ALT, creatinine, pro-BNP and troponin) between unvaccinated and vaccinated patients (P<0.05). Unvaccinated patients were more likely to experience COVID-19-related outcomes, including pneumonia (51.6% vs 26.2%), respiratory support [40.7% vs 13.5%], invasive ventilation or death [6.2% vs 0.7%]. Multivariate regression analysis showed that vaccination was associated with early virus shedding [aHR＝1.594, 95%CI (1.259, 2.017)], and protected against progression to pneumonia [aOR＝0.501, 95%CI (0.370, 0.678)], respiratory support [aOR＝0.336, 95%CI (0.232, 0.487)], invasive ventilation or death [aOR＝0.190, 95%CI (0.052, 0.687)] in elderly patients. Our findings suggest that inactivated vaccine protects against COVID-19-related severe outcomes in individuals aged over 60 years.
孙峰1, 张忆琳1, 李杨1, 张昊澄1, 刘其会1, 艾静文1, 王森1, 崔书正2，史留斌2，薛愉2，龙丰2，马可2，钦伦秀2，张继明1，张文宏1. 接种新冠灭活疫苗对老年奥密克戎变异株感染者临床转归的保护作用——一项基于医院队列的研究[J]. 微生物与感染, 2022, 17(4): 209-219.
SUN Feng1, ZHANG Yilin1, LI Yang1, ZHANG Haocheng1, LIU Qihui1, AI Jingwen1, WANG Sen1, CUI Shuzheng2, SHI Liubin2, XUE Yu2, LONG Feng2, MA Ke2, QIN Lunxiu2, ZHANG Jiming1, ZHANG Wenhong1. Inactivated vaccine protects against severe outcome among adults aged over 60 years during SARS-CoV-2 Omicron variant predominance: evidence from a single-center cohort. JOURNAL OF MICROBES AND INFECTIONS, 2022, 17(4): 209-219.
2022, Vol. 17 
